

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

AMNEAL PHARMACEUTICALS LLC and AMNEAL
PHARMACEUTICALS OF NEW YORK, LLC,
Petitioners,

v.

ALMIRALL, LLC
Patent Owner

Case IPR2019-00207
U.S. Pat. No. 9,517,219

PETITIONERS' EXHIBIT LIST

Mail Stop "PATENT BOARD"
Patent Trial and Appeal Board
U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

<i>Amneal Exhibit #</i>	<i>Description</i>
1001	U.S. Patent No. 9,517,219
1002	Declaration of Bozena B. Michniak-Kohn, Ph.D., FAAPS, M.R.Pharm.S.
1003	<i>Curriculum Vitae</i> for Bozena B. Michniak-Kohn, Ph.D., FAAPS, M.R.Pharm.S.
1004	International Patent Application Publication No. WO 2009/061298 (“Garrett”)
1005	International Application Publication No. WO 2010/072958 (“Nadau-Fourcade”)
1006	Certification for Translation of WO 2010/072958
1007	U.S. Patent Publication No. 2006/0204526 (“Lathrop”)
1008	U.S. Patent Publication No. 2010/0029781 (“Morris”)
1009	Osborne, D.W., “Diethylene glycol monoethyl ether: an emerging solvent in topical dermatology products,” <i>J. Cosmetic Derm.</i> 10:324-329 (2011) (“Osborne I”)
1010	<i>Physician’s Desk Reference</i> , 65 th ed., pp. 599-602 (2011) (ACZONE Gel 5% Label)
1011	U.S. Patent No. 7,820,186 (“Orsoni”)
1012	Epiduo Product Label, approved December 8, 2008 (“Epiduo Label”)
1013	U.S. Patent Publication No. 2007/0190019 (“Guo”)
1014	Rowe, R.C. et al. (Eds.), <i>Handbook of Pharmaceutical Excipients</i> , 6th Ed., Pharmaceutical Press: London, UK (2009)
1015	Bonacucina, G., <i>et al.</i> , “Characterization and Stability of Emulsion Gels Based on Acrylamide/Sodium Acryloyldimethyl Taurate Copolymer,” <i>AAPS PharmaSciTech</i> 10:368-375 (2009) (“Bonacucina”)
1016	U.S. Patent No. 5,863,560 (“Osborne II”)
1017	File History of U.S. Patent No. 9,517,219
1018	Declaration of Elaine S. Gilmore, M.D., Ph.D.

<i>Amneal Exhibit #</i>	<i>Description</i>
1019	<i>Curriculum Vitae</i> for Elaine S. Gilmore, M.D., Ph.D.
1020	Affidavit of Christopher Butler
1021	<i>Intentionally left blank</i>
1022	Wozel, D., "Innovative Use of Dapsone" <i>Dermatol. Clin.</i> 28: 599–610 (2010) ("Wozel")
1023	Thiboutot, D., <i>et al.</i> , "Pharmacokinetics of Dapsone Gel, 5% for the Treatment of Acne Vulgaris" <i>Clin. Pharmacokinet.</i> 46: 697-712 (2007) ("Thiboutot")
1024	Nguyen, R. and Su, J., "Treatment of Acne Vulgaris" <i>Pediatrics and Child Health</i> 21: 119-125 (2010) ("Nguyen")
1025	Williams, H., <i>et al.</i> , "Acne vulgaris" <i>Lancet</i> 379: 361–72 (2012) ("Williams")
1026	Sepineo™ P 600 Brochure
1027	Barclay, L., "Use of Topical Corticosteroids for Dermatologic Conditions Reviewed" <i>Medscape</i> - Jan 21, 2009, accessed from https://www.medscape.com/viewarticle/587159_print ("Barclay")
1028	Remington: The Science and Practice of Pharmacy, 21st Ed., Lippincott Williams & Wilkins: Baltimore, MD (2005) ("Remington")
1029	Kim, J-Y., <i>et al.</i> , "Rheological properties and microstructures of Carbopol gel network system," <i>Colloid. Polym. Sci.</i> 281:614–623(2003) ("Kim")
1030	<i>Intentionally left blank</i>
1031	Spain's Almirall bets on dermatology with \$650 million U.S. deal, Retrieved from https://www.reuters.com/article/us-allergan-m-a-almirall/spains-almirall-bets-on-dermatology-with-650-million-us-deal-idUSKBN1KO10N , last accessed October 26, 2018
1032	Piskin, S. <i>et al.</i> "A review of the use of adapalene for the treatment of acne vulgaris," <i>Therapeutics and Clinical Risk Management</i> 3(4): 621–624 (2007) ("Piskin")
1033	<i>Intentionally left blank</i>

<i>Amneal Exhibit #</i>	<i>Description</i>
1034	Andersson, D., "Evonik-Degussa expands its cooperation with Alsiano," <i>Pharma & Healthcare News</i> : 1-10 (2007)

10252301_1.docx

Respectfully submitted,
STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Date: November 6, 2018
1100 New York Avenue, N.W.
Washington, DC 20005-3934
(202) 371-2600

Dennies Varughese, Pharm.D.
Registration No. 61,868
Attorney for Petitioners

CERTIFICATE OF SERVICE (37 C.F.R. § 42.6(e), 42.105(a))

The undersigned hereby certifies that the above-captioned “Petitioners’ Exhibit List”, along with exhibits 1001 – 1034, were served in their entirety on November 6, 2018, upon the following parties via FedEx®:

Allergan, Inc
2525 Dupont Drive, T2-7H
Irvine, CA 92612-1599
*Patent owner's correspondence
address of record for
U.S. Patent No. 9,517,219*

Almirall, LLC
2525 Dupont Drive, T2-7H
Irvine, CA 92612-1599
*Additional address known to
Petitioner as likely to effect service*

Litigation counsel of record:

James S. Trainor, Jr.
FENWICK & WEST LLP,
902 Broadway, Suite 14,
New York, NY 10010

Elizabeth B. Hagan
Ewa M. Davison
FENWICK & WEST LLP,
1191 Second Avenue, 10th Floor,
Seattle, Washington 98101

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Date: November 6, 2018
1100 New York Avenue, N.W.
Washington, DC 20005-3934
(202) 371-2600

Dennies Varughese, Pharm.D.
Registration No. 61,868
Attorney for Petitioners